Rigel Reports R343 Fails To Meet Endpoints In Phase 2 Asthma Study - Quick Facts

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients with allergic asthma, did not meet the primary or secondary endpoints in a Phase 2 clinical study. The company has decided not to pursue this indication with R343. The primary endpoint was the change in pre-bronchodilator FEV1, a measure of lung function, from baseline to dosing completion at Week 8, comparing active doses to placebo.

"This was not the result we expected based on the collection of data we had previously seen with R343 in this therapeutic area," said James Gower, chairman and chief executive officer of Rigel.